Congratulations to Dr. Huabei Jiang who was recently highlighted in a Reuters.com article (posted below) for an award he received for the invention of the JBI-360 Breast Imaging System. Dr. Jiang was honored with a 2015 Technology Innovator Award during the UF Office of Technology Licensing’s A Celebration of Innovation event earlier this year.
Originally posted by Reuters.com on May 5, 2015
Advanced fPAT Imaging Inc. (AFPII), a new medical device company focused on early detection of breast cancer, announced today that its Chief Scientific Advisor was honored by the University of Florida Research Foundation for developing a new breast imaging and disease staging technology. Dr. Jiang is a Pruitt Family Professor of Biomedical Engineering at the University of the Florida and a recognized leader in innovative medical imaging research. The JBI-360 Imaging System uses his exciting new technology, called Functional PhotoAcoustic Imaging or ‘fPAT,’ to create high-resolution maps of key physiological markers within the breast without x-ray radiation, compression, or injections. For the first time, radiologists and oncologists can non-invasively observe physiology and metabolic activity associated with suspicious lesions using a single device.
In early clinical trials, the JBI-360 demonstrated its ability to see into dense breast tissue and to distinguish healthy tissue from suspicious or unhealthy tissue. Clinical studies have demonstrated that dense breast tissue can impede diagnosis of breast cancer with both digital and newer 3D tomographic mammography techniques. In comparison, the new fPAT imaging device overcomes this problem — providing high-quality images of the breast regardless of tissue density.
“The JBI-360 has great potential for both early breast cancer diagnosis and cancer treatment monitoring (neo-adjuvant therapy),” Dr. Jiang said. “Because fPAT is more sensitive to breast microvascular density, it will provide brand-new insights currently unavailable with non-optical imaging techniques. This new information can be used to investigate the functioning of tumors within the breast in order to enhance diagnosis and prognosis.”
The worldwide diagnostic imaging is a $32 billion marketplace and is expected to grow to $49 billion by 2020. The company is currently seeking seed capital and welcomes any inquiries from potential investors.
Contact: Michael Addley, CEO, AFPII